Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06058702 · ClinicalTrials.gov registry record · Phase 1

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

A Phase 1 study of Schizophrenia and Cannabis Use Disorder, sponsored by Yale University.

Recruiting
Registry status
Phase 1
Development phase
215
Enrollment target
1
Study location

NCT06058702 is a Phase 1 study of Schizophrenia and Cannabis Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 215 participants, roughly in line with the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06058702, a Phase 1 study of Schizophrenia and Cannabis Use Disorder, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 1
Development phase
215 participants
Enrollment target
1
Study location

Study Summary

Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher potency of cannabis, the availability of highly potent cannabinoid products, the commercialization of cannabis, and the rising rates of cannabis use, it is critical to understand how genetic factors influence 1) an individual's vulnerability for addiction and psychosis, 2) the response to cannabinoids, 3) the response to novel treatments for CanUD. CanUD is strongly genetically influenced; the investigators published the first CanUD genomewide association study (GWAS) with genomewide-significant results; however, the precise nature of the contribution of genetic factors in the development of CanUD is still not clear. Cannabis exposure has also been linked to a number of psychosis outcomes including schizophrenia (SCZ). SCZ is highly heritable and population-based and genetics studies both support a bidirectional genetic relationship between SCZ and CanUD. However, the precise contribution of genetic factors in the development of psychosis outcomes related to cannabis are not clear.

Conditions Studied

Schizophrenia Cannabis Use Disorder

Interventions

  • DRUG Placebo
  • DRUG Delta-9-THC Medium Dose
  • DRUG Delta-9-THC Very Low Dose

Study Locations (1)

Connecticut

  • West Haven Veterans Affairs Medical Center - West Haven

Trial Details

FieldValue
Enrollment Target 215 participants
Start Date 2024-09-16
Est. Completion 2028-12-31
Phase Phase 1

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06058702

The ClinicalTrials.gov registry entry for NCT06058702 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06058702 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT06058702 about?

NCT06058702 is a clinical study titled "Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans". Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher potenc...

What is the current status of trial NCT06058702?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 215 participants. The study started on 2024-09-16. Estimated completion is 2028-12-31.

What conditions does trial NCT06058702 study?

This clinical trial studies the following conditions: Schizophrenia, Cannabis Use Disorder.

What interventions are being tested in trial NCT06058702?

The interventions under investigation include: Placebo (DRUG), Delta-9-THC Medium Dose (DRUG), Delta-9-THC Very Low Dose (DRUG).

Who is sponsoring clinical trial NCT06058702?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06058702 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Cannabis Use Disorder

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.